Takeda Pharmaceutical Co Ltd: Q2 FY2021 Financial Summary
Business Context and Reporting Period
This Form 6-K filing summarizes the consolidated financial results for Takeda Pharmaceutical Company Limited for the six-month period ended September 30, 2021 (Fiscal Year 2021 H1). The company operates globally with core therapeutic areas in Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Immunology, Oncology, and Neuroscience. The filing was submitted on October 28, 2021.
Key Financial Metrics
| Metric | Value (JPY) | YoY Change |
|---|---|---|
| Revenue | 1,794.4 Billion | +12.8% |
| Operating Profit | 346.0 Billion | +60.5% |
| Profit Before Tax | 284.4 Billion | +126.5% |
| Net Profit (Attributable to Owners) | 183.6 Billion | +112.2% |
| Basic EPS | 117.08 JPY | +111.0% |
| Core Operating Profit | 485.7 Billion | -4.3% |
| Core EPS | 214 JPY | -3.2% |
| Total Assets | 12,560.3 Billion | -2.7% (vs FYE Mar 2021) |
| Total Equity | 5,324.4 Billion | +2.8% (vs FYE Mar 2021) |
| Cash & Equivalents | 607.9 Billion | -37.1% (vs FYE Mar 2021) |
| Bonds & Loans | 4,231.4 Billion | -8.8% (vs FYE Mar 2021) |
Cash Flow: Net cash from operating activities was 400.0 Billion JPY. Net cash used in investing activities was 103.3 Billion JPY. Net cash used in financing activities was 658.4 Billion JPY, driven by debt repayments.
Material Changes vs. Prior Period
- Revenue Growth: Reported revenue increased 12.8% year-over-year. This includes a one-time gain of 133.0 Billion JPY from the sale of a diabetes portfolio in Japan to Teijin Pharma Limited. Excluding this sale and foreign exchange impacts, underlying revenue growth was 6.8%.
- Profit Surge: Net profit more than doubled (+112.2%) primarily due to a significant one-time gain in the prior year related to the release of an obligation to divest the SHP647 pipeline compound, which is absent in the current period, combined with higher operating profits.
- Therapeutic Area Performance:
- Gastroenterology: Revenue up 13.0%, driven by ENTYVIO (+23.6%) and TAKECAB (+22.9%).
- PDT Immunology: Revenue up 15.6%, driven by GAMMAGARD LIQUID and albumin products.
- Rare Diseases: Revenue up 1.6%, with growth in Rare Metabolic offset by declines in Rare Hematology due to competition.
- Oncology: Revenue up 11.3%, led by VELCADE and ADCETRIS.
- Neuroscience: Revenue up 12.5%, driven by VYVANSE/ELVANSE (+20.1%).
- Debt Reduction: Bonds and loans decreased by 404.0 Billion JPY due to the redemption of senior notes and prepayment of the Japan Bank for International Cooperation (JBIC) loan.
Guidance, Outlook, and Risks
Full Year Forecast Revision (FY Ending March 31, 2022):
- Net Profit: Revised downward to 184.3 Billion JPY (from 250.0 Billion JPY), a decrease of 26.3%.
- EPS: Revised downward to 117.35 JPY (from 159.91 JPY).
- Reason for Revision: The reduction is due to a tax charge of approximately 63.7 Billion JPY (including interest) arising from an Irish tax assessment on a break fee received from AbbVie in 2014 regarding the terminated Shire acquisition.
- Core Metrics: Core Operating Profit (930.0 Billion JPY) and Core EPS (394 JPY) remain unchanged as the tax charge is excluded from core results.
Management Guidance:
- Underlying Revenue Growth: Mid-single-digit growth.
- Underlying Core Operating Profit Growth: Mid-single-digit growth.
- Underlying Core Operating Profit Margin: ~30%.
Risks and Contingencies:
- Tax Assessment: The Irish tax charge is a significant non-recurring item impacting reported net profit.
- COVID-19: While no material financial impact was observed in H1, the company notes potential future disruptions to demand, supply chains, and clinical trials.
- Competition: Intensified competition in Rare Hematology and generic erosion for products like AMITIZA and VELCADE (outside the U.S.).
- Divestitures: Ongoing divestitures of non-core assets may impact comparability.
Investor Verification Checklist
- Tax Charge Impact: Verify the final amount and timing of the Irish tax assessment charge and its effect on full-year cash taxes.
- Underlying vs. Reported: Distinguish between reported growth (inflated by the diabetes portfolio sale) and underlying growth (6.8% revenue, 6.4% core operating profit) to assess organic performance.
- Debt Maturity Profile: Review the schedule of bond redemptions and loan prepayments to assess future liquidity requirements.
- Product Pipeline: Monitor the status of new launches (e.g., REVESTIVE in Japan) and the impact of generic entry on key products like AMITIZA and VELCADE.
- Share Buyback: Note the Board's resolution on October 28, 2021, to repurchase up to 35 million shares (approx. 100 Billion JPY) to enhance capital efficiency.